Guggenheim Rates GeneDx (WGS) buy, $74 Price Target

Guggenheim Maintains Bullish Stance on GeneDx

Analyst Subbu Nambi from Guggenheim reiterated a Buy rating on GeneDx Holdings Corp. (NASDAQ: WGS) on June 29, 2026. The firm set a price target of $74.00 for the stock, which was trading at $68.65 on Monday at the time of the update. This call suggests the analyst sees room for the stock to rise from its current levels, even as the company continues to work toward full profitability.

This rating update follows a period where the company has focused heavily on its pediatric and rare disease diagnostics. By leveraging whole exome and genome sequencing, GeneDx is trying to capture a larger slice of the specialized genetic testing market. The $74.00 target from Guggenheim was an increase from their previous target of $70.00, showing a slight lift in expectations for the company's trajectory.

GeneDx Stock Performance and Market Context

GeneDx shares have seen a lot of volatility lately. The stock price of $68.65 is currently sitting below its 50-day moving average of $77.96 and its 200-day moving average of $81.82. While the stock is well above its 52-week low of $32.21, it has pulled back considerably from the yearly high of $170.87. With a market capitalization of roughly $2.92 billion, the company remains a mid-sized player in the healthcare diagnostics space.

The stock's beta of 2.01 suggests it moves twice as much as the broader market, which can lead to the sharp price swings investors have seen over the past year. Despite the recent price drop, the forward P/E ratio stands at 83.70, suggesting that some investors are still pricing in significant future earnings growth.

Recent Earnings and Growth Metrics

GeneDx reported revenue of $454.43 million in its most recent financial period, which was an 11.4% increase compared to the previous year. While the top line is growing, the company is still losing money on a net basis. It reported an EPS of -$3.63 and a negative return on equity of 40.8%. Its net margin also remains in the red at -23.4%.

However, the company's balance sheet appears stable for now. GeneDx has a current ratio of 3.30, which means it has over three times the assets it needs to cover its short-term debts. Investors are looking toward October 27, 2026, for the next scheduled earnings report to see if the company can narrow its losses and improve its margins.

Analysts Set New Price Targets

Guggenheim is not the only firm watching GeneDx closely. On October 1, 2026, Guggenheim actually raised its target again to $83.00 while maintaining a Buy rating. Earlier in the summer, on August 4, 2026, both Canaccord Genuity and BTIG maintained Buy ratings with $90.00 price targets. Piper Sandler also weighed in on June 23, 2026, keeping an Overweight rating but setting a lower target of $63.00.

Across the nine analysts who cover the stock, the consensus remains positive. The average price target among these experts is $90.44, with a high estimate of $103.00 and a low of $74.00. Most of these firms seem to agree that the company's genomic sequencing technology is a valuable asset, even if the path to profitability is taking time.

Genomics and AI Diagnostics

GeneDx Holdings Corp. provides genetic testing services with a specific focus on rare diseases and pediatric care. Founded in 2000 and based in Stamford, Connecticut, the company has evolved to include an AI-based platform that helps clinicians interpret complex genomic data. This technology is designed to make hereditary risk and cancer testing faster and more accurate.

As the company moves toward its next earnings release in October, market participants will likely focus on whether the 11.4% revenue growth can accelerate. The gap between the current share price and the $90.44 average analyst target suggests that Wall Street expects a recovery if the company can hit its financial milestones.